Severity: Warning
Message: file_get_contents(https://...@gmail.com&api_key=61f08fa0b96a73de8c900d749fcb997acc09&a=1): Failed to open stream: Network is unreachable
Filename: helpers/my_audit_helper.php
Line Number: 197
Backtrace:
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 197
Function: file_get_contents
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 271
Function: simplexml_load_file_from_url
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 1075
Function: getPubMedXML
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 3195
Function: GetPubMedArticleOutput_2016
File: /var/www/html/application/controllers/Detail.php
Line: 597
Function: pubMedSearch_Global
File: /var/www/html/application/controllers/Detail.php
Line: 511
Function: pubMedGetRelatedKeyword
File: /var/www/html/index.php
Line: 317
Function: require_once
98%
921
2 minutes
20
Aims: Excessive hepatic glucose production (HGP) driven by glucagon contributes to hyperglycaemia in obesity and type 2 diabetes (T2D), yet the molecular mechanisms underlying this dysregulation remain incompletely defined. This study investigates the role of Smad3 signaling and its regulation by CHIP (Carboxy-terminus of Hsc70-interacting protein) in modulating glucagon action on HGP.
Materials And Methods: We examined glucagon signaling and HGP in primary hepatocytes and in high-fat diet (HFD)-induced obese (DIO) mice. Mechanistic studies included hepatic knockdown of CHIP and Smad3, assessment of Smad3 protein stability, ubiquitination assays, and quantification of gluconeogenic gene expression.
Results: We identified Smad3 as a key mediator of glucagon-induced HGP, synergizing with TGF-β1 signaling to enhance gluconeogenic gene G6pc expression in a Foxo1-dependent manner. Glucagon elevated Smad3 protein levels by inhibiting CHIP-mediated ubiquitination, thereby increasing Smad3 stability. CHIP expression was downregulated in the livers of DIO mice. Hepatic CHIP knockdown augmented glucagon-stimulated HGP and increased Smad3 levels, whereas simultaneous knockdown of Smad3 reversed these effects.
Conclusions: Our findings reveal a novel CHIP-Smad3 regulatory axis that enhances glucagon action on HGP in obesity. Targeting this pathway may offer a new therapeutic strategy for improving glycaemic control in T2D.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12232369 | PMC |
http://dx.doi.org/10.1111/dom.16493 | DOI Listing |